

BNA President/ Professor of Neuroscience, Royal Holloway, University of London



Plus more speakers to be announced soon.....

Deputy Chief Medical Officer, Scendea
I am a Principal Medical Consultant at Scendea, responsible for providing highly strategic clinical and regulatory advice. I was formerly a Leading Senior Medical Assessor at the MHRA and represented the UK in the European working groups on new trial designs, safety and In Vitro Diagnostics. I am one of the authors of the CTFG Recommendation Paper on the Initiation and Conduct of Complex Clinical Trials. I was involved in the UK response to both the Ebola and the COVID19 medical emergencies.
BNA President/ Professor of Neuroscience, Royal Holloway, University of London
Professor Ramnani is a distinguished Professor of Neuroscience at Royal Holloway, University of London, where his research group uses functional neuroimaging to understand brain organisation, and brain mechanisms that govern higher cognitive function, learning processes, and the control of action.
He is also Vice Dean for EDI at Royal Holloway’s School of Life Sciences and the Environment. Beyond his university roles, he is a member of the Parliamentary and Scientific Committee APPG Advisory Group. He also makes contributions to equity, diversity, and inclusion through his contributions to the BNA Scholars programme, his role on the BBSRC's Expert EDI Advisory Group and his governance role as a member of the Governance Committee of Advance HE's Race Equality Charter. A commitment to fostering a strong, collaborative, and inclusive research community underscores the priorities he brings to the Presidency.

Lead Scientist, Medicines Discovery Catapult
Paul is a Senior Preclinical Imaging Scientist with over 15 years of experience in driving innovation in translational research within academia and industry.
Paul has a PhD in neuroscience and expertise across multiple therapeutics areas from oncology to CNS disorders, with a strong focus on applying anatomical and functional imaging modalities for disease phenotyping, PK/PD readouts and evaluating whole-body biodistribution of complex medicines.

Chief Scientific and Clinical Advisor/Co-Founder, AviadoBio
Professor Shaw had trained as a Neurologist in New Zealand before coming to Cambridge, UK on a Wellcome Trust Fellowship and moving to King’s College London in 1995. He is Director of the Maurice Wohl Clinical Neuroscience Institute, and Centre Director of the UK Dementia Research Institute at King’s. His research team have discovered more amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) genes than any other laboratory, enabling gene testing for patients and at-risk family members. They have generated a large number of stem cell and transgenic mouse models that recapitulate key features of the human disease and have revealed important mechanistic insights. Their focus for the future is to develop gene therapies for a wide range of neurodegenerative disorders using adeno-associated viral gene vectors. Award highlights include the “Forbes Norris Award” for Amyotrophic Lateral Sclerosis Care and Research (2009), “Sheila Essey Prize” for Amyotrophic Lateral Sclerosis Research (2012) and “Kea World Class New Zealander Award” (2019). He remains clinically active, running an ALS clinic at King’s College Hospital and leading clinical trials of antisense oligonucleotide therapies.

Professor of Translational Drug Discovery, Cardiff University
Professor Simon WardPlease accept {{cookieConsents}} cookies to view this content